Stories

Clinical guidance on e-cigarettes is moving from avoidance towards structured, evidence-informed advice. The SRNT recommendations recognise that adult smokers are already asking clinicians about vaping, and that many need options beyond traditional cessation tools. That shift matters because shared decision-making requires more than caution; it requires clear comparisons between continued smoking, complete switching and nicotine abstinence. Harm reduction belongs in the clinical conversation when it helps patients move away from combustion.

Nicotine’s history is far more complex than the way it is usually discussed. The same substance has been framed as poison, dependence driver, medicine and harm reduction tool, depending on dose, delivery and context. That matters because public health debates often flatten nicotine into a single moral category. Better policy starts by separating the substance from the smoke, the risk from the rhetoric, and the product from the purpose it may serve.

Australia’s tobacco excise debate shows how quickly public health policy can become an organised crime opportunity. Extremely high taxes may be designed to discourage smoking, but they can also make illegal cigarettes profitable enough to sustain violence, corruption and a market beyond normal controls. Enforcement alone cannot fix incentives this large. A credible strategy should reduce smoking while keeping consumers inside legal channels and making lower-risk nicotine alternatives easier to access than illicit tobacco.

“They don’t count” captures one of the deepest failures in nicotine policy. Smokers, vapers and users of safer nicotine products are often treated as statistics, problems or collateral damage rather than people whose choices determine whether harm is reduced in practice. A global war on nicotine can lose sight of the real target: disease and death caused by smoking. Public health should count the people it claims to protect, especially those trying to move away from combustion.

Clinicians now have stronger grounds to discuss nicotine e-cigarettes as part of smoking cessation care. The JAMA recommendations recognise that adult smokers need patient-centred advice on the full range of evidence-based options, including vaping where appropriate. That matters because misperceptions about relative risk can keep people tied to cigarettes even after repeated quit attempts. Medical guidance should be clear enough to help smokers move away from combustion, while still explaining limits, uncertainty and the need to switch completely.

Proposed vaping restrictions should be judged not only by their intention, but by their cost to public health. Hiding or limiting lower-risk products may reduce visibility, but it can also make switching less likely for adult smokers who still need a route away from cigarettes. A policy that discourages vaping while smoking remains available risks protecting the wrong behaviour. Regulation should target youth access and irresponsible retailing without weakening one of the most practical exits from combustion.

The gateway theory has shaped nicotine policy for years, often turning vaping into a presumed pathway to smoking rather than a potential route away from it. Challenging that assumption matters because policy should follow observed behaviour, not fears repeated until they sound like evidence. Research that separates correlation from causation can help clarify whether safer nicotine products are driving harm or displacing cigarettes. Public health needs that distinction before it builds restrictions around a theory.

Australia’s illicit tobacco crisis cannot be solved by raids alone. The Coalition’s plan recognises a hard lesson: organised crime thrives where taxes create huge margins, legal alternatives are restricted and consumers are pushed outside regulated channels. Cutting criminal profit must go hand in hand with bringing vapes and nicotine pouches into an accountable adult market. Public health is stronger when enforcement, taxation and harm reduction all point in the same direction.

Tobacco control loses credibility when opposition to industry turns into opposition to harm reduction itself. Cigarette companies deserve scrutiny, but that does not make every argument for safer nicotine products a tobacco industry tactic. Adult smokers are poorly served by a debate that treats reduced-risk options as contamination rather than opportunity. Public health should be able to reject industry misconduct while still recognising evidence that helps people move away from combustion.

Bans can remove legal access, but they do not remove demand. Nicotine markets continue through informal supply, cross-border purchasing and illicit sellers once regulated options are pushed out of reach. That leaves consumers with fewer safeguards and authorities with less control. Harm reduction works better by shaping demand through legal, accountable routes than by pretending demand can be legislated away.